Drug Database
CE

cefalexin pivoxil (Sigmacef / Viasporin / Medicef)

✓ Approved

Leadiant Biosciences, Inc · 小分子 · 小分子

什么是 cefalexin pivoxil?

cefalexin pivoxil 是一种小分子,由Leadiant Biosciences, Inc研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Sigmacef, Viasporin, Medicef
公司Leadiant Biosciences, Inc
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

cefalexin pivoxil 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsSalmonellosis✓ Approved

相关研究文献

PubMedClinical drug investigation2026-11-04

Tebipenem Pivoxil Tablet Formulation: First Approval.

Shirley Matt M

Tebipenem pivoxil is an orally available carbapenem prodrug with antibacterial activity against a range of Gram-negative and some Gram-positive bacterial pathogens. A fine granule formulation of tebipenem pivoxil (Orapenem®) was approved in Japan in 2009 and is indicated for use in the treatment of pneumonia, otitis media and sinusitis in paediatric patients. More recently, Spero Therapeutics in collaboration with GSK has developed a high-drug-content tebipenem pivoxil tablet formulation (UTEBZI), containing the hydrobromide salt of tebipenem pivoxil, for oral administration. In June 2026, the tebipenem pivoxil tablet formulation received its first approval, in the USA, where it is indicated for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain specified susceptible pathogens in adult patients who have limited or no alternative oral treatment options. This article summarises the milestones in the development of the tebipenem pivoxil tablet formulation leading to this first approval for the treatment of cUTIs, including pyelonephritis, in adults.

PMID 42980745
阅读全文 →
PubMedBiosensors & bioelectronics2026-11-02

Domain fusion modulates antibody recognition without altering the parental scFv sequence for multi-residue screening of β-lactam antibiotics under MRL constraints.

Wen Hao H, Ding Mingyue M, Jiang Shuang S, Wen Defeng D et al.

Broad-spectrum detection of structurally diverse small molecules is often limited by the trade-off between specificity and recognition breadth. Here, we present a domain fusion strategy to modulate antibody recognition behavior without altering the parental scFv sequence. A bifunctional fusion protein, BlaR-M-scFv, was engineered by integrating receptor- and antibody-based recognition within a single framework, enabling broad-spectrum screening of β-lactam antibiotics at regulatory maximum residue limits (MRLs) in complex matrices. The fusion protein exhibited an expanded recognition spectrum compared with the parental scFv, indicating altered recognition behavior. Domain separation experiments showed that the isolated domains retained their characteristic recognition properties, consistent with a contribution of interdomain coupling to the altered recognition behavior. Molecular dynamics (MD) simulations suggested that fusion was associated with remodeling of the scFv conformational landscape, resulting in a more constrained yet spatially permissive state. In the ligand-bound state, structural and energetic analyses suggested a redistribution of interaction networks and altered interaction geometry. These changes are consistent with increased tolerance toward structural variation among β-lactam antibiotics, accompanied by reduced apparent recognition strength for the specific ligand cefalexin compared with the parental scFv under the same assay conditions. This work suggests that domain fusion may provide a means of modulating antibody recognition through conformational regulation and offers a potential strategy for developing multi-residue screening immunoassays for β-lactam antibiotics.

PMID 42970902
阅读全文 →
PubMedCureus2026-10-29

Thoracic Actinomycosis Mimicking Tuberculosis Presenting as Pneumonia and a Chest Wall Mass.

Fayyaz Mohsin M, Joy M A Sayed MAS, Limaye Manasi M, Khan Shaheryar S et al.

Thoracic actinomycosis is an uncommon chronic infection caused by Actinomyces species. It can produce pulmonary consolidation and extend across tissue planes into the chest wall, closely mimicking tuberculosis or malignancy. A previously well woman in her 20s presented with 2-3 weeks of left posterolateral chest wall pain, progressive swelling, weight loss of 2-3 kg, cough and haemoptysis. She had had two earlier episodes of left-sided pneumonia treated with short antibiotic courses. Examination showed a large (>10 cm), warm, firm, non-fluctuant swelling over the left posterolateral chest wall. Blood tests showed a marked inflammatory response (white blood cell count (WBC): 16.2 × 10⁹/L, C-reactive protein (CRP): 168-169 mg/L) and microcytic anaemia. CT demonstrated superoposterior left lower lobe consolidation with perifissural nodules, volume loss, reactive lymph nodes and a contiguous chest wall collection. Tuberculosis was considered first. Ultrasound-guided biopsy showed a heterogeneous, septated mass with necrosis. Acid-fast bacillus (AFB) staining, tuberculosis polymerase chain reaction (PCR) and mycobacterial culture at eight weeks were negative. Histology showed granulation tissue and abscess with filamentous Gram-positive aggregates suggestive of Actinomyces. Actinomyces was not isolated in culture. She improved on intravenous co-amoxiclav and completed a prolonged oral β-lactam course, later changed to cefalexin after microbiology review. This case illustrates the difficulty of diagnosing thoracic actinomycosis when it presents with contiguous pulmonary and chest wall disease. Histology supported a presumptive diagnosis. Actinomycosis should be considered when chronic pulmonary infection extends into the chest wall, particularly after tuberculosis has become substantially less likely.

PMID 42953265
阅读全文 →
PubMedCancers2026-10-16

From Infection to Oncology: AI-Assisted Drug Repurposing Uncovers Anti-Infective and Excipient-Class Compounds as PPAR-α-Linked Anticancer Agents.

Ikhlas Shoeb S, Alsharidah Amani A, Alkhodier Reem A RA, Senar Sergio S et al.

Drug repurposing offers an efficient strategy to identify novel anticancer agents from marketed compounds. We screened a library of ~1400 approved drugs using a PPARE-PPAR-α luciferase reporter assay to uncover modulators of lipid metabolism that induce cancer cell death without direct binding to PPARα. This primary screen identified 224 compounds inhibiting reporter activity by >50%, of which 26 demonstrated ≥50% cytotoxicity in KAIMRC1 breast cancer and HCT116 colorectal cancer cells at 10 µM after 48 h incubation. AI-based DrTarget analysis classified these hits, with Group 1 comprising four previously unrecognized anticancer agents: antibiotics cefditoren pivoxil, tebipenem pivoxil, broxyquinoline, and cosmetic ingredient 1-hexadecanol. Dose-response studies across KAIMRC1, HCT116, and SW480 cells revealed IC50 values as low as ~10 µM, comparable to daunorubicin, a well-known anti-cancer drug. Apoptosis profiling confirmed activation of intrinsic/extrinsic pathways via cytochrome c, SMAC/Diablo, TRAIL-R1/DR4, and phospho-p53 modulation. Based on these findings, we propose the repurposing of Broxyquinoline, 1-Hexadecanol, Cefditoren Pivoxil, and Tebipenem Pivoxil as potential anti-cancer drugs.

PMID 42882925
阅读全文 →
PubMedInfection2026-10-04

Oral tebipenem pivoxil for complicated urinary tract infections: evidence, potential role in IV-to-oral transition, and antimicrobial stewardship.

Alkhanafsa Mohammed M, Wafi Jamil J, Deek Soud S

Complicated urinary tract infections (cUTIs), including pyelonephritis, are increasingly challenging when resistant Enterobacterales eliminate conventional oral treatment options. Tebipenem pivoxil (UTEBZI), approved by the US Food and Drug Administration in June 2026, is the first oral carbapenem approved in the United States for selected adults with cUTI. This review evaluates its pharmacology, microbiological activity, efficacy, safety, and potential role in intravenous (IV)-to-oral treatment and antimicrobial stewardship METHODS: A structured narrative review of PubMed/MEDLINE, regulatory documents, clinical-trial reports, guidelines, pharmacokinetic/pharmacodynamic studies, microbiological studies, and relevant oral step-down literature was conducted through 12 August 2026. Priority was given to randomized phase 3 trials, FDA prescribing information, and IDSA guidance RESULTS: ADAPT-PO and PIVOT-PO demonstrated noninferiority of complete oral tebipenem regimens to IV ertapenem and IV imipenem-cilastatin, respectively, with high clinical cure rates. Tebipenem retains activity against many ESBL- and AmpC-producing Enterobacterales but lacks reliable activity against major carbapenemases. Neither phase 3 trial randomized clinically improving patients after initial IV therapy; therefore, direct randomized evidence for a formal tebipenem step-down strategy is lacking. Important uncertainties include limited bacteremia data, every-six-hour adherence, optimal post-IV duration, cost-effectiveness, microbiome effects, and resistance selection CONCLUSION: Tebipenem is an important culture-directed oral option for selected adults with cUTI when narrower effective oral agents are unavailable. Its most defensible early role is replacement of otherwise necessary continued IV carbapenem therapy in carefully selected patients, with source control, susceptibility confirmation, renal doseadjustment, safety screening, duration planning, and stewardship oversight. Dedicated switch, bacteremia, implementation, and resistance-surveillance studies remain needed.

PMID 42828629
阅读全文 →
PubMedClinical therapeutics2026-09-28

UTEBZI (tebipenem pivoxil).

Beninger Paul P, Pinto Larissa Garcia LG

PMID 42805880
阅读全文 →

注册免费账户还可查看另外 845 篇文献

免费注册查看全部文献 →

了解更多cefalexin pivoxil